RELATIONSHIP BETWEEN ANTIPYRINE METABOLISM AND ACETYLATION PHENOTYPE IN HEALTH AND CHRONIC LIVER-DISEASES

被引:5
作者
ELYAZIGI, A
RAINES, DA
WAHAB, FA
SIECK, JO
ERNST, P
ALI, H
DOSSING, M
机构
[1] KING FAISAL SPECIALIST HOSP & RES CTR,DEPT MED,RIYADH 11211,SAUDI ARABIA
[2] KING FAISAL SPECIALIST HOSP & RES CTR,DEPT ONCOL,RIYADH 11211,SAUDI ARABIA
关键词
D O I
10.1002/j.1552-4604.1995.tb05019.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The authors examined the activity of N-acetyltransferase and that of microsomal P-450 isoenzymes in health and hepatic disease state by determining the acetylation phenotype and the total (CL(AP)) and metabolic clearances of antipyrine to form norantipyrine or N-demethylantipyrine (MCL(nora)), 3-hydroxymethylantipyrine (MCL(hma)), and 4-hydroxyantipyrine (MCL(ha)) in 21 healthy subjects and in 33 patients with chronic liver diseases (CLD) and investigated the relationship between the activities of these two enzyme systems. The acetylation phenotype was determined according to the urinary caffeine metabolites test. The mean and (SEM) of CLAP, MCL(hma), MCL(ha), and MCL(nora) in healthy subjects were 2.42 (0.264), 0.193 (0.031), 0.322 (0.045), and 0.288 (0.04) L/h, and those observed in patients with CLD were 0.98 (0.1), 0.076 (0.015), 0.131 (0.026), 0.103 (0.022) L/h, respectively. The prevalence of fast acetylation among the healthy subjects and patients with CLD was 38% and 39%, respectively. Although all metabolic clearances appear to be reduced in healthy slow acetylators, the reduction was only significant in MCL(nora), indicating a direct association between the activity of N-acetyltransferase and that of P-450 IIIA3 responsible for the N-demethylation of antipyrine. Conversely, slow acetylators with CLD exhibited significantly higher CLAP and near-significantly larger metabolic clearances including MCL(nora), which suggests that P-450 activity in fast acetylators is more sensitive to chronic liver diseases than in slow acetylators.
引用
收藏
页码:615 / 621
页数:7
相关论文
共 11 条
[1]   COMPARISON OF THE INVIVO AND INVITRO RATES OF FORMATION OF THE 3 MAIN OXIDATIVE METABOLITES OF ANTIPYRINE IN MAN [J].
BOOBIS, AR ;
BRODIE, MJ ;
KAHN, GC ;
TOVERUD, EL ;
BLAIR, IA ;
MURRAY, S ;
DAVIES, DS .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 12 (06) :771-777
[2]   A SIMPLE METHOD FOR DETERMINATION OF ANTIPYRINE CLEARANCE [J].
DOSSING, M ;
POULSEN, HE ;
ANDREASEN, PB ;
TYGSTRUP, N .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1982, 32 (03) :392-396
[3]   SIMPLIFIED DETERMINATION OF ANTIPYRINE CLEARANCE BY LIQUID-CHROMATOGRAPHY OF A MICROSAMPLE OF SALIVA OR PLASMA [J].
ELYAZIGI, A ;
RAINES, DA ;
ALI, H ;
SIECK, J ;
ERNST, P ;
DOSSING, M .
PHARMACEUTICAL RESEARCH, 1991, 8 (02) :269-272
[4]  
ELYAZIGI A, 1989, CLIN CHEM, V35, P848
[5]   VARIABILITY IN CAFFEINE METABOLISM [J].
GRANT, DM ;
TANG, BK ;
KALOW, W .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 33 (05) :591-602
[6]   A SIMPLE TEST FOR ACETYLATOR PHENOTYPE USING CAFFEINE [J].
GRANT, DM ;
TANG, BK ;
KALOW, W .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 17 (04) :459-464
[7]   POLYMORPHIC N-ACETYLATION OF A CAFFEINE METABOLITE [J].
GRANT, DM ;
TANG, BK ;
KALOW, W .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 33 (03) :355-359
[8]   ANTIPYRINE AS A MODEL-DRUG TO STUDY HEPATIC DRUG-METABOLIZING CAPACITY [J].
POULSEN, HE ;
LOFT, S .
JOURNAL OF HEPATOLOGY, 1988, 6 (03) :374-382
[9]   ANTIPYRINE CLEARANCE AND METABOLITE FORMATION IN PATIENTS WITH ALCOHOLIC CIRRHOSIS [J].
TEUNISSEN, MWE ;
SPOELSTRA, P ;
KOCH, CW ;
WEEDA, B ;
VANDUYN, W ;
JANSSENS, AR ;
BREIMER, DD .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 18 (05) :707-715
[10]   AUTOMATED HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF ANTIPYRINE AND ITS MAIN METABOLITES IN PLASMA, SALIVA AND URINE, INCLUDING 4,4'-DIHYDROXY-ANTIPYRINE [J].
TEUNISSEN, MWE ;
MEERBURGVANDERTORREN, JE ;
VERMEULEN, NPE ;
BREIMER, DD .
JOURNAL OF CHROMATOGRAPHY, 1983, 278 (02) :367-378